Developing medicines is a minefield that Tranzyme Pharma has navigated well so far. But the Durham company is about to embark on one of its trickiest missions.
Posts Tagged ‘Tranzyme’
RTP Wrapup 12/11
Friday, December 11, 2009, 12:11 am No Comments | Post a CommentTranzyme Pharma signs on to help Bristol-Myers Squibb fight generic competition, RTI International receives a $101 million contract to fight malaria in Africa and a drug safety expert at the Hamner Institutes for Health Sciences teams up with a geneticist at N.C. State University to find out why some patients have serious liver reactions to otherwise safe drugs. Read more…
Next: A crucial decision
Thursday, September 3, 2009, 8:23 am 1 Comment | Post a CommentThis is the last part. Continued from part 2.
Getting a ghrelin drug to market
Thursday, September 3, 2009, 8:20 am No Comments | Post a CommentThis is the second part of three. Continued from part 1.
Work on promising ghrelin medicines has gotten to a critical stage a decade after Japanese researchers discovered the hormone that stimulates hunger and is linked to insulin production.
Ghrelin: A new hormone is found
Thursday, September 3, 2009, 8:15 am No Comments | Post a CommentINTRODUCTION
Tranzyme Pharma is one of dozens of drug development companies in North Carolina’s Research Triangle area, a biotech hot spot that is ranked third in the nation by number of companies. The Durham company has diligently advanced therapies based on a hormone that was discovered a decade ago, a technology also used by two rivals. Now, Tranzyme’s Board of Directors has to decide how to pay for the final development step and get its drugs to market: Go public, sell the company or go back to its investors hat in hand one more time.
This is the first part of three.
RTP Wrapup 8/28
Thursday, August 27, 2009, 6:27 pm No Comments | Post a CommentDuke University Health System announced plans for a $700 million cancer center, GlaxoSmithKline’s diet pill Alli is being investigated for possibly causing serious liver damage and Wall Street observers project a flurry of companies may try to go public after Labor Day.
Next: A crucial decision
Tuesday, July 28, 2009, 9:14 am No Comments | Post a CommentThis is the last part. Continued from part 2.
Developing medicines is a minefield that Tranzyme Pharma has navigated well so far. But the Durham company is about to embark on one of its trickiest missions.
Getting a ghrelin drug to market
Tuesday, July 14, 2009, 11:38 am No Comments | Post a CommentThis is the second part of three. Continued from part 1.
Work on promising ghrelin medicines has gotten to a critical stage a decade after Japanese researchers discovered the hormone that stimulates hunger and is linked to insulin production.
Ghrelin: A new hormone is found
Monday, July 6, 2009, 9:24 am No Comments | Post a CommentINTRODUCTION
Tranzyme Pharma is one of dozens of drug development companies in North Carolina’s Research Triangle area, a biotech hot spot that is ranked third in the nation by number of companies. The Durham company has diligently advanced therapies based on a hormone that was discovered a decade ago, a technology also used by two rivals. Now, Tranzyme’s Board of Directors has to decide how to pay for the final development step and get its drugs to market: Go public, sell the company or go back to its investors hat in hand one more time.
This is the first part of three.
A rising star
Friday, June 19, 2009, 6:54 am No Comments | Post a CommentVipin Garg, the chief executive of Tranzyme Pharma, a small Durham drug development company, has the credentials to get invited to official events in the Research Triangle area, such as the opening of Quintiles Transnational’s new headquarters last month. But until now, he has shown no appetite for stepping out into the limelight himself.
The Entrepreneur of the Year awards program, run by Ernst & Young, one of the four big business auditing companies, is changing that.
